Lactococcus Lactis GEN3033 Metabolite Secretion for Anticancer Immunity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current anticancer agents face challenges such as side effects on normal cells, resistance development, and variable therapeutic responses due to genetic variations, necessitating the need for novel, targeted approaches that can effectively inhibit cancer cell proliferation and metastasis while enhancing immune response.

Innovation Solution

Development of novel Bifidobacterium bifidum MG731 and Lactococcus lactis GEN3033 strains, which inhibit cancer cell proliferation, decrease mobility, regulate neoangiogenesis, and enhance immune activity through specific metabolic actions, potentially combined with existing chemotherapeutic and immunotherapeutic agents.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional anticancer agents are used, then cancer cell proliferation is inhibited, but side effects on normal cells occur and resistance develops

Engineering Contradiction:

Improveanticancer efficacyVSAvoidside effects on normal cells

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent segments the anticancer approach by using specific probiotic strains (Bifidobacterium bifidum MG731 and Lactococcus lactis GEN3033) that selectively target cancer cells through their metabolic activities, rather than using broad-spectrum conventional agents that affect all rapidly dividing cells. This segmentation allows for cancer-specific inhibition while preserving normal cell function.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The probiotic strains act as intermediaries that modulate the tumor microenvironment and immune response. They secrete metabolites that indirectly inhibit cancer cell proliferation and enhance immune-mediated cancer cell death, rather than directly killing cancer cells like conventional agents, thereby reducing harmful side effects.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If conventional anticancer agents are used, then cancer cell proliferation is inhibited, but resistance development occurs

Engineering Contradiction:

Improveanticancer efficacyVSAvoidtherapeutic response duration

Core Design Contradiction:

ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The probiotic strains establish continuous presence in the gut and tumor microenvironment, providing sustained anticancer effects through ongoing secretion of metabolites and continuous modulation of immune response. This continuous action prevents resistance development that occurs with intermittent conventional chemotherapy.

Inventive Principle:

Principle #20Continuity of useful action

Solution Approach 2:

The patent changes the biochemical parameters of the tumor microenvironment by introducing probiotic strains that alter pH, oxygen tension, and metabolite concentrations. These parameter changes create a hostile environment for cancer cells that is difficult for them to adapt to, preventing resistance.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If probiotic strains are used to inhibit cancer cell proliferation, then immune response is enhanced, but the mechanism involves complex metabolic activities

Engineering Contradiction:

Improveimmune enhancementVSAvoidmetabolic mechanism complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The probiotic strains perform self-service by autonomously secreting metabolites and modulating the immune system without requiring external intervention. The strains establish themselves in the gut and tumor microenvironment, where they continuously produce anticancer metabolites and enhance immune response through their inherent metabolic activities.

Inventive Principle:

Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The strains exhibit enhanced anticancer effects by inhibiting cancer cell proliferation, reducing metastasis, and regulating immune responses, with improved outcomes when used alone or in combination with conventional treatments, addressing resistance and side effects.

Implementation Method 1

inhibit cancer cell proliferation, decrease mobility, and regulate the expression of genes involved in neoangiogenesis

Methodology Applied

Scientific EffectMetabolic actions:

Implementation Method 2

enhances immune activity by secreting metabolites having an anticancer efficacy while being established in the gut

Methodology Applied

Scientific EffectMetabolite secretion:

Data Source

PatentUS12564613B2Strains having effects of preventing or treating cancers

Publication Date: 2026.03.03 GENOME & CO INC

AI summary

The present invention relates to a novel Lactococcus lactis GEN3033 strain and a composition for preventing or treating cancers, comprising the same. Specifically, the Lactococcus lactis GEN3033 strain of the present invention exhibits effects of directly inhibiting the proliferation of cancer cells and enhancing immunity, thereby having effects of preventing or treating cancers. In particular, the strain has an excellent anticancer effect by secreting metabolites having an anticancer effect while being established in the gut. In addition, when used in combination with an anticancer chemotherapeutic agent or an anticancer immunotherapeutic agent, the Lactococcus lactis GEN3033 strain of the present invention exhibits a better anticancer effect.